Literature DB >> 25249370

Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.

Tadeusz Robak1.   

Abstract

Anti-CD20 monoclonal antibodies (mAbs), rituximab, ofatumumab and obinutuzumab, have a significant impact in the treatment of chronic lymphocytic leukemia (CLL), particularly in combination with chemotherapy. Over the last few years, several new mAbs have been developed and investigated in CLL. The most promising newer mAbs are directed against CD20, CD19, CD37 and CD40. Combinations of antibodies with targeted drugs like ibrutinib, idelalisib or lenalidomide will probably replace chemotherapy-based combinations in the near future. This review gives a critical overview of established mAbs as well as new antibodies potentially useful in CLL.

Entities:  

Keywords:  CD19; CD20; CD23; CD37; CD40; CD52; CLL; GA-101; MOR208; TRU-016; dacetuzumab; lucatumumab; lumiliximab; ocrelizumab; ofatumumab; otlertuzumab; veltuzumab

Mesh：

Substances：

Year:  2014        PMID： 25249370     DOI： 10.1586/17474086.2014.963048

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN： 1747-4094            Impact factor:   2.929


  5 in total

Review 1.  Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1.

Authors:  Michael Y Choi; George F Widhopf; Christina C N Wu; Bing Cui; Fitzgerald Lao; Anil Sadarangani; Joy Cavagnaro; Charles Prussak; Dennis A Carson; Catriona Jamieson; Thomas J Kipps
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-06

2.  Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia.

Authors:  Maulik Vyas; Ann-Charlott Schneider; Olga Shatnyeva; Katrin S Reiners; Samir Tawadros; Stephan Kloess; Ulrike Köhl; Michael Hallek; Hinrich P Hansen; Elke Pogge von Strandmann
Journal:  Oncoimmunology       Date:  2016-07-15       Impact factor: 8.110

Review 3.  Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.

Authors:  Karen Seiter; Aleksandra Mamorska-Dyga
Journal:  Clin Interv Aging       Date:  2015-06-12       Impact factor: 4.458

4.  Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset.

Authors:  Stephan Kloess; Alessa Ede Valverde da Silva; Olaf Oberschmidt; Tanja Gardlowski; Nadine Matthies; Maulik Vyas; Lubomir Arseniev; Michael Heuser; Elke Pogge von Strandmann; Ulrike Köhl
Journal:  Front Immunol       Date:  2017-09-08       Impact factor: 7.561

5.  The immunohistochemical analysis of membrane-bound CD55, CD59 and fluid-phase FH and FH-like complement inhibitors in cancers of ovary and corpus uteri origin.

Authors:  Lucyna Kapka-Skrzypczak; Ewa Wolinska; Grzegorz Szparecki; Magdalena Czajka; Maciej Skrzypczak
Journal:  Cent Eur J Immunol       Date:  2015-10-15       Impact factor: 2.085
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.